Sarjan Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 21-12-2024
- Paid Up Capital ₹ 1.40 M
as on 21-12-2024
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 3.35 Cr
as on 21-12-2024
- Revenue -20.21%
(FY 2022)
- Profit 99.76%
(FY 2022)
- Ebitda -10.45%
(FY 2022)
- Net Worth -35.80%
(FY 2022)
- Total Assets -28.37%
(FY 2022)
About Sarjan Bio-Tech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.40 M.
The company has closed loans amounting to ₹3.35 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Harish Nagda and Pinkesh Nagda serve as directors at the Company.
- CIN/LLPIN
U74220GJ2005PTC046114
- Company No.
046114
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 May 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Kachchh, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sarjan Bio-Tech Private Limited offer?
Sarjan Bio-Tech Private Limited offers a wide range of products and services, including Fruit Plants, Banana Plant, Fresh Flowers, Plants & Trees, Plant Tissue Culture, Banana Tissue Culture Plants.
Who are the key members and board of directors at Sarjan Bio-Tech?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Harish Nagda | Managing Director | 20-May-2005 | Current |
Board Members(1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Pinkesh Nagda | Director | 30-Mar-2022 | Current |
Financial Performance of Sarjan Bio-Tech.
Sarjan Bio-Tech Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 20.21% decrease. The company also saw a substantial improvement in profitability, with a 99.76% increase in profit. The company's net worth observed a substantial decline by a decrease of 35.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Sarjan Bio-Tech?
In 2020, Sarjan Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Axis Bank Limited Creation Date: 28 Feb 2013 | ₹5.00 M | Satisfied |
Axis Bank Limited Creation Date: 01 Oct 2005 | ₹1.95 Cr | Satisfied |
Axis Bank Limited Creation Date: 20 Sep 2005 | ₹8.99 M | Satisfied |
How Many Employees Work at Sarjan Bio-Tech?
Unlock and access historical data on people associated with Sarjan Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sarjan Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sarjan Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.